Original Article | J Adv Med Biomed Res. 2022; 30(138): 24-29
Journal of Advances in Medical and Biomedical Research | ISSN:2676-6264
Association between Diabetes and Controlling Risk Factors with Survival
Rate in Colorectal Cancer
Marjan Sharifi Nasab1,2
, Hamideh Yazdimoghaddam3,4*
, Seyedeh Tahereh Mohaddes5
Mohammad Hassan Rakhshani
,
6,7
1. Dept. of Nursing, Faculty of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran
2. Dept. of Nursing, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
3. Dept. of Operating Room, Faculty of Paramedics, Sabzevar University of Medical Sciences, Sabzevar, Iran
4. Iranian Research Center on Healthy Aging, Sabzevar University of Medical Sciences, Sabzevar, Iran
5. Dept. of Hematology & Medical Oncology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences,
Mashhad, Iran
6. Dept. of Biostatistics and Epidemiology, School of Public Health, Sabzevar University of Medical Sciences, Sabzevar, Iran
7. Iranian Research Center on Healthy Aging, Sabzevar University of Medical Sciences, Sabzevar, Iran
Article Info
ABSTRACT
10.30699/jambs.30.e56391
Received: 2020/09/12;
Accepted: 2021/01/25;
Published Online: 17 Nov 2021;
Use your device to scan and read the
article online
Article URL: Link
Corresponding Information:
Hamideh Yazdimoghaddam,
Dept. of Operating Room, Faculty of
Paramedics, Sabzevar University of
Medical Sciences, Sabzevar, Iran.
E-Mail:
ha_yazdimoghaddam@yahoo.com
Background & Objective: Colorectal cancer (CRC) is a highly prevalent
malignancy leading to death across the world. However, patient survival is greatly
affected following a diagnosis of diabetes. The purpose of this research was to study
the correlation between diabetes and controlling risk factors with the survival rate
of colorectal cancer patients.
Materials & Methods: This retrospective follow‐up study was done on 356 patients
with colorectal cancer, who had been diagnosed during 1999-2013. Notably, the
patients were selected using systematic random sampling. The patients were allocated
into two groups according to the history of diabetes and its absence. The survival rate
of the patients was assessed during the follow-up period up to 2018.
Results: In colorectal cancer patients, the diabetes prevalence was 11%. The mean
survival rate in patients with CRC and non-colorectal non-diabetic was 5.541±0.227
years and in diabetic patients was 0.508 ±5.246 years. No significant difference was
apperceived in the survival rate of the diabetic and non-diabetic patients (P = 0.57).
The risk of mortality in patients with CRC who were not treated with insulin increased
and their survival decreased (P= 0.05). In metastatic stage of lymph nodes, it was
0.314 higher in patients with the metastasis to distant regions (P = 0.000).
Conclusion: Based on the results, training diabetic patients regarding effective
therapies in controlling risk factors, hyperglycemia, and screening for rapid
diagnosis of CRC are essential to improve health and increase survival rate in
diabetic patients.
Keywords: Diabetes Mellitus, Insulin, Survival, Colorectal Neoplasms, Neoplasm
Metastasis
Copyright © 2022, This is an original open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits
copy and redistribution of the material just in noncommercial usages with proper citation.
Introduction
Today, cancer is a main public health threat across
the world especially in developing countries (1).
Colorectal cancer (CRC) is the third most common
cancer and affecting 1.23 million persons (9.7% of
all cancer types) annually (2). CRC is the third
leading cause of death in the United States (3). CRC
is the fourth most common cancer in men and the
second most common in women in Iran. Recent
researches have indicated rapid progress in the
incidence of CRC in Iran (2017). As well, CRC was
reported as the fifth cause of mortality in males and
the fourth in females (4).
Volume 30, January & February 2022
CRC is the most common gastrointestinal cancer,
and its outbreak has increased over the last 25 years,
and Iranian data show younger age distribution than
Western reports (5). Overall, CRC is ranked third in
incidence and second in mortality rates. CRC
incidence rates vary widely (6). The statistic of new
cancer cases is anticipated to increase, and cancers
causing death are also predicted to reach over 11.4
million in 2030 across the world, manifesting
cancers to be the major cause of death (7).
Based on the scientific reports, Out of 40% of
cancers could be prevented by decreasing the risk
Journal of Advances in Medical and Biomedical Research
Marjan Sharifi Nasab et al. 25
factors (8). The correlation between type II diabetes and
some cancers has been identified, while this diagnostic
complexity is remarkably increasing. Some types of
cancer, especially CRC are affected by some risk factors,
including diabetes, insulin resistance, age, gender,
socioeconomic status, obesity, insulin resistance, diet,
alcohol consumption, physical activity, and smoking
habits (9). The global prevalence of diabetes is a risk
factor for more seriously considering the disease (10). In
addition, some research studies have investigated to
identify the mechanisms of how diabetes and cancer are
associated together (11). In the study by Fedeli et al.
(2014), different types of biological pathways, such as
hyperinsulinemia, hyperglycemia, and persistent antiinflammatory status have been reported as risk factors
for cancer in diabetes (12).
There is an association between type 2 diabetes and
increased colon, breast, pancreatic, and other cancers.
The risk of cancer in diabetic patients increases because
of the rising prevalence of diabetes, the extensive use of
insulin analogs, as well as other anti-diabetic drugs,
which gives presuppositions regarding cancer risk in the
diabetic population (13).
Recently, some factors have also been identified to
increase the risk of cancer, such as insulin glargine. It
has raised concerns about the increasing use of insulin;
since studies have shown that insulin is related to a raised
risk of cancer (14), while metformin appears to be
related to a decreased risk of cancer and mortality (15).
Moreover, diabetic patients were reported to have a
poor prognosis after cancer diagnosis as well as
increasing cancer risk (10).
Evidence has shown an increased mortality rate
caused by colorectal, breast, endometrial, kidney, liver,
and pancreatic in patients with diabetes. Nevertheless, it
remains unclear whether or not diabetes is an
independent risk factor for the mentioned neoplasms
(10, 16).
On the other hand, several reasons have been shown
to decrease survival in diabetic patients after diagnosis
of cancer (10), including increased tumor cell
proliferation
due
to
hyperinsulinemia
and
hyperglycemia, different methods of cancer treatment,
poor response to cancer therapy in diabetic patients, as
well as inadequate diabetes management during cancer
treatment. Though, these data have been poorly
evaluated and require further investigation.
Despite receiving multiple treatments, the survival
rate of these patients declines due to the metastatic
nature of cancer (9). However, the diagnosis of cancer
patients with diabetes increases the complications in
the treatment process, which in turn reduces the
survival rate. Therefore, the purpose of this research
was to study the correlations between diabetes and
controlling risk factors, such as smoking, obesity,
insulin resistance, and drug therapy with the five-year
survival rate in CRC patients.
Volume 30, January & February 2022
Materials and Methods
This retrospective follow‐up study was conducted to
analyze the patients' data diagnosed with CRC receiving
treatment at clinics affiliated with Mashhad University of
Medical Sciences.
Participants
The research populations were patients with diagnosed
CRC from 1999 to 2013 referred to the oncology
department of Imam Reza and Ghaem Hospital, and also
Isar Chemotherapy Center.
The inclusion criteria of the study were the patients
with a pathological diagnosis of colorectal carcinoma
and age of more than 18 years. On the other hand, the
exclusion criteria consisted of family history of CRC,
incomplete treatment of cancer due to leaving the
hospital with personal consent, and failure to complete
the treatment. After receiving approvals from the Ethics
Committee of the university, the medical records related
to the 1999-2013 period were selected by systematic
random sampling, and the related variables were
systematically extracted.
Demographic and clinical information of patients were
collected through a questionnaire accurately to assess risk
factors and history of diabetes.
Overall, the following demographic and clinical data
were collected for medical records of 356 desirable
patients. Then the patients were divided into two groups
based on the history of diabetes and its absence. The
patients diagnosed with CRC were followed up to
evaluate survival time up to five years since the diagnosis
to investigate the relationship between diabetes and risk
factors with survival rate.
The mean follow‐up period was 5.0±0.1 years.
CRC diagnosis was confirmed based on the criteria
of the International Classification of Pathologies and
Diseases (ICD), the American Commission on
Cancer, and the pathology report. To make a diabetes
mellitus (DM) diagnosis, fasting blood sugar (FBS)
and HbA1c tests were precisely carried out. Diagnosis
or detection of diabetes (FBS levels ≥126 mg/dl) at
recurrence was recorded.
Statistical Analysis
Data analysis was fulfilled in SPSS version 17
(Chicago, IL, USA) using descriptive statistics, t-test or its
nonparametric equation, Mann-Whitney U test, Chisquare, and Cox proportional hazards model to assess risk
factors and hazard ratio (HR) in the diabetic and nondiabetic CRC patients. In all the statistical analysis, the Pvalue of less than 0.05 was considered significant.
Ethical consideration
This research was approved by the Sabzevar University
of Medical Sciences (Ref : 97081 ) and Ethics Committee
of Sabzevar University of Medical Sciences, sabzevar,
Iran (ethical code: IR.MEDSAB.REC.1397.020).
Journal of Advances in Medical and Biomedical Research
26 Diabetes and Survival of Colorectal Cancer Patients
Results
The mean age of the diabetic and non-diabetic CRC
patients was 65.00(12.61) and 55.47(15.05),
respectively. The demographic characteristics of the
participants consisted of gender, marital status,
residence, and job status. The results of the Fisher’s
exact test and Chi-square test demonstrated no
significant differences between diabetic and nondiabetic patients (p>0.05).
The mean duration of diabetes in patients with CRC
was 10.38 ±7.38. Evaluation of cancer risk factors in the
two diabetic and non-diabetic groups indicated that 97.4%
of the diabetic patients and 95.0% of non-diabetic patients
had negative smoking habits. The results of Fisher’s exact
test demonstrated no significant differences between
diabetic and non-diabetic patients (P=0.58).
In addition, other risk factors, such as the Body Mass
Index (BMI), mean and standard deviation of in the
diabetic group was 25.66 (2.75) and in the non-diabetic
group was 24.56 (4.64). Mann-Whitney test demonstrated
a significant difference between the two groups (P= 0.04).
According to the histopathological diagnosis, 51.3%
of diabetic patients and 46.1% of non-diabetic patients
were in the non-metastatic stage. However, Chi-square
results demonstrated no significant difference between
diabetic and non-diabetic patients (P = 0.51). The results
related to tumor markers (e.g., CEA and CA19-9 in
CRC) are presented in Table 1.
Table 1: Frequency distribution of tumor markers for patients with CRC
Tumor Markers
CEA
CA19-9
Patient
Mean (SD)
Diabetic
20.01 (28.75)
Non Diabetic
58.94 (314.12)
Diabetic
59.87 (115.18)
Non Diabetic
141.18 (913.19)
Based on the findings, the prevalence of diabetes was
11% in CRC patients, and the mean duration of
diabetes was 10.38±7.38 years. About chronic
complications after diabetes, 59.0% of diabetic patients
with CRC had no chronic complications after diabetes
and 33.3% had hypertension.
Concerning controlling risk factors, such as diabetes
controlling drugs; 87.2% of the patients used metformin
and glibenclamide; while 7.7% of the subjects consumed
metformin. Moreover, 79.5% of the patients had no
history of insulin therapy, and the history of insulin
therapy in diabetic patients was 5 (2.53) years.
The mean survival rate of non-diabetic and diabetic
patients with CRC was 5.541±0.227 and 5.246 ±0.508
years, respectively.
To investigate the impacts of diabetes on the survival
rate of CRC patients in the presence of effective
factors, such as age, gender, smoking, BMI, residence,
marital status, occupation, tumor stage, and CEA tumor
P- Value
0.03
0.23
marker, the related data were fitted in the Cox
regression model. However, the findings indicated no
significant difference between survival time of diabetic
and non-diabetic patients (95% CI: 0.709 – 1.860; HR:
1.149; P = 0.57).
Based on the above-mentioned risk factors, for the tumor
stage, the mortality risk significantly decreased in patients
with the non-metastatic stage (0.180 equal) compared to
other patients and in the metastatic stage of lymph nodes
(0.314 equal) compared to the patients with metastasis to
distant regions, and their survival rate increased.
Analysis of the Cox regression model for diabetes
control drugs demonstrated that the risk of mortality
increased in CRC patients who were not treated with
insulin (2.568 equal) and their survival rate decreased
(95% CI: 1.023 – 6.447; HR: 2.568; P = 0.05). In CRC
cases, the effects of risk factors and using drugs on the
survival rate of diabetic and non-diabetic patients are
presented in Table 2.
Table 2: The Effect of Diabetes, Risk Factors, and Drugs on the Survival Rate of Patients with CRC
Variable
HR
95% CI
P- Value
diabetes
1.149
0.709-1.860
0.57
non-metastatic stage
0.180
0.122-0.266
0.000
lymph node metastasis
0.314
0.205-0.483
0.000
insulin
2.568
1.023-6.447
0.05
Volume 30, January & February 2022
Journal of Advances in Medical and Biomedical Research
Marjan Sharifi Nasab et al. 27
Discussion
According to the overview of CRC survival rates in
Asia, mortality rates remain high (17). Recent evidence
has suggested that CRC is the fifth cause of mortality in
men and the fourth in women (4). In the current study, no
significant difference was discovered between diabetic
and non-diabetic groups in terms of the survival rate,
which is consistent with the study by Karlin et al. (18).
Therefore, it seems that diabetes does not independently
affect the survival rate. Though mortality in the diabetic
patients was over than that of the non-diabetic patients and
the mean survival was reduced. Therefore, the impact of
diabetes as a risk factor on cancer deaths cannot be
ignored. In another study, De Bruijn et al. (2013)
considered diabetes as a risk factor for CRC and cancer
death (19). In similar research, Rosato et al. also found a
positive association between diabetes and CRC (20). This
discrepancy between the present study findings and the
aforementioned studies might be due to metformin use in
diabetic patients with CRC, which increased the survival
rate of the subjects. In summary, further investigation is
recommended to confirm the present study findings.
History evaluation based on anti-diabetic drugs
revealed a significant decrease in the survival rate of
patients who were not treated with insulin. In a study by
Rosato et al. a positive association was found between
insulin use and CRC (20). Moreover, Dąbrowski et al.
reported that HbA1c ≥8.5%, insulin treatment in a dosedependent manner, and time-varying method, had a
significant association with a raised risk of malignancy
(21). Also, a study by Call et al. has shown that the rate of
tumor growth progression in the presence of insulin
analogs has been increased. However, the positive effects
of insulin therapy on decreasing diabetes-related deaths
were greater than these risks (14). Hyperglycemia directly
or indirectly causes DNA damage, DNA breaks, mutation
accumulation, and impairment in DNA repair, by
changing the expression of oncogenes and tumor
suppressor genes using various mechanisms (22). Induced
mutations in oncogenes and tumor suppressor genes
stimulate cancer cell proliferation, which can reduce the
survival rate of diabetic patients with CRC (11).
Therefore, physicians should regularly screen cancer
patients receiving insulin and monitor tumor growth or
disease recovery (14). Lack of proper control of chronic
hyperglycemia in diabetes is associated with serious
clinical consequences, leading to long-term complications,
such as retinopathy, peripheral neuropathy, nephropathy,
peripheral vascular disease, ischemic heart disease, stroke,
limb complications, and infections (22).
The results of the present study revealed a significant
decrease in survival time in CRC patients with distant
metastasis. Ahmadi et al. have reported that the incidence
of death in the non-metastatic and metastatic CRC with
lymph node involvement was lower than patients with
distant metastasis (23); since in the non-metastatic stage,
there was a better response to cancer treatment. However,
in the metastatic phase, the response to treatment is poor.
The results of the systematic review and meta-analysis by
Volume 30, January & February 2022
Tahmasbi et al. have revealed a relationship between
tumor metastasis and the survival rate of the patients in a
way that the mortality risk of patients with metastasis who
were referred to other centers was 3.26 times more than
those without it (24). A study by Akhoond et al. has
reported that the mortality risk of individuals with tumor
metastasis who were referred to other centers was 3.577
for colon cancer and 2.646 for rectum cancer compared to
those without it (25).
The evaluation of risk factors revealed that the BMI
of diabetic patients with CRC was higher than nondiabetic patients. Erickson et al. concluded that the
overall risk of mortality was twice higher in the women
with the HbA1C level of ≥%7.0 after modifying the
confounding factors compared to the subjects with
HbA1C level less than 6.5% (26), which might be due
to the reduced susceptibility to anti-angiogenic
regimens (27). Obesity raises the prevalence of CRC
and affects outcomes, overall and in association with
specific CRC treatments (28). Murphy et al. reported
that obesity increases the risk of colon cancer mortality
especially among males (29). Due to the importance of
metabolic syndrome and insulin resistance, BMI was
recognized as a risk factor in the diagnosis of diabetic
patients with CRC. Despite different results, training
diabetic patients regarding risk factors of CRC, such as
BMI, and effective therapies in controlling
hyperglycemia, such as insulin, and also CRC
screening in the early stages of CRC are essential for
the improvement of diabetic patients health and
increasing their survival rate.
Conclusion
The high prevalence of CRC is an important public
health issue. According to the study results, diabetic
patients are at risk of developing types of cancer,
especially CRC due to drug treatments and the presence
of risk factors. Therefore, screening is important.
Due to the increased survival in insulin-treated patients,
the treatment of hyperglycemia in diabetic patients with
CRC is important. The reduced risk of death in patients
with non-metastatic and metastatic CRC with Lymph
node involvement suggests the importance of secondlevel prevention in the timely treatment of CRC.
Therefore, early screening of diabetic patients by
physicians, for faster diagnosis of CRC in early stages and
timely treatment and prevention of metastasis can
improve their survival.
According to the results of the study, in the followup survival of patients with CRC and diabetes, due to
the increased risk of death in patients with metastasis
to distant sites, Identification of risk factors, early
diagnosis, and education of diabetic patients
regarding control of hyperglycemia with effective
therapies could help increase the survival of diabetic
patients with CRC.
Journal of Advances in Medical and Biomedical Research
28 Diabetes and Survival of Colorectal Cancer Patients
Acknowledgment
This article is derivative from the Master's thesis in
nursing approved by Sabzevar University of Medical
Sciences with code 97081. Hereby, thanks are owed to the
authorities of the hospitals affiliated with Mashhad
University of Medical Sciences for their assistance in
conducting this research project.
Conflicts of Interest
There is no conflict of interest.
References
1.
Malvezzi M, Carioli G, Bertuccio P, et al.
European cancer mortality predictions for the year
2018 with focus on colorectal cancer. Ann Oncol.
2018
29(4):1016-22.
[DOI:10.1093/annonc/mdy033] [PMID]
2.
Dolatkhah R, Somi MH, Kermani IA, et al.
Increased colorectal cancer incidence in Iran: a
systematic review and meta-analysis. BMC public
health. 2015 15(1):997. [DOI:10.1186/s12889015-2342-9] [PMID] [PMCID]
3.
Kasper DL, Hauser SL, Fauci AS, et al. Harrisons
internal medicine. 19th, editor. United States of
America: MCGraw-Hill; 2015.
4.
Organization WH. Country Cancer Profile.
Available
from:
http://www
who
int/cancer/country-profiles/chn_en pdf. 2014
[Accessed 5 may 2021].
5.
6.
7.
8.
9.
Pourhoseingholi MA, Zali MR. Colorectal cancer
screening: Time for action in Iran. World J
Gastrointest
Oncol.
2012;4(4):82-3.
[DOI:10.4251/wjgo.v4.i4.82] [PMID] [PMCID]
Bray F, Ferlay J, Soerjomataram I, et al. Global
cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers
in 185 countries. CA Cancer J Clin.
2018;68(6):394-424. [DOI:10.3322/caac.21492]
[PMID]
Bray F, Jemal A, Grey N, et al. Global cancer
transitions according to the Human Development
Index (2008-2030): a population-based study.
Lancet
Oncol.
2012;13(8):790-801.
[DOI:10.1016/S1470-2045(12)70211-5]
Jemal A, Center MM, DeSantis C, et al. Global
patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 2010
19(8):1893-907. [DOI:10.1158/1055-9965.EPI10-0437] [PMID]
Wild S. Diabetes, treatments for diabetes and their
effect on cancer incidence and mortality: attempts
to disentangle the web of associations.
Diabetologia.
2011;54(7):1589-92.
[DOI:10.1007/s00125-011-2169-6] [PMID]
Volume 30, January & February 2022
10. Onitilo AA, Engel JM, Glurich I, et al. Diabetes
and cancer I: risk, survival, and implications for
screening.
Cancer
Causes
Control.
2012;23(6):967-81. [DOI:10.1007/s10552-0129972-3] [PMID] [PMCID]
11. Collins KK. The diabetes-cancer link. Diabetes
Spectr.
2014;27(4):276-80.
[DOI:10.2337/diaspect.27.4.276]
[PMID]
[PMCID]
12. Fedeli U, Zoppini G, Gennaro N, et al. Diabetes
and cancer mortality: a multifaceted association.
Diabetes research and clinical practice.
2014;106(3):e86-e9.
[DOI:10.1016/j.diabres.2014.09.027] [PMID]
13. Pandey A, Forte V, Abdallah M, et al. Diabetes
mellitus and the risk of cancer. Minerva
endocrinologica. 2011;36(3):187-209.
14. Call R, Grimsley M, Cadwallader L, et al. Insulincarcinogen or mitogen? Preclinical and clinical
evidence from prostate, breast, pancreatic, and
colorectal cancer research. Postgrad Med.
2010;122(3):158-65.
[DOI:10.3810/pgm.2010.05.2153] [PMID]
15. Lee JH, Kim TI, Jeon SM, et al. The effects of
metformin on the survival of colorectal cancer
patients with diabetes mellitus. Int J Cancer.
2012;131(3):752-9.
[DOI:10.1002/ijc.26421]
[PMID]
16. Behrouzi B, Mohagheghi MA, Sadighi S.
Demographic Characteristics, Survival and
Prognostic Factors of Early Breast Cancer Patients
with Type 2 Diabetes Mellitus: A Hospital-Based
Cohort Study. APJCP. 2017; 18(9):2485.
17. Moghimi-Dehkordi B, Safaee A. An overview of
colorectal cancer survival rates and prognosis in
Asia. World J Gastrointest Oncol. 2012;4(4):71.
[DOI:10.4251/wjgo.v4.i4.71] [PMID] [PMCID]
18. Karlin NJ, Amin SB, Kosiorek HE, et al. Survival
and glycemic control in patients with colorectal
cancer and diabetes mellitus. Future Sci OA. 2018;
4(9):FSO335.
[DOI:10.4155/fsoa-2018-0044]
[PMID] [PMCID]
19. De Bruijn K, Arends L, Hansen B, et al. Systematic
review and meta‐analysis of the association
between diabetes mellitus and incidence and
mortality in breast and colorectal cancer. Br J Surg.
2013;100(11):1421-9.
[DOI:10.1002/bjs.9229]
[PMID]
20. Rosato V, Tavani A, Gracia-Lavedan E, et al. Type
2 diabetes, antidiabetic medications, and colorectal
cancer risk: two case-control studies from Italy and
Spain. Front Oncol. 2016;6:210.
[PMID]
[DOI:10.3389/fonc.2016.00210]
[PMCID]
Journal of Advances in Medical and Biomedical Research
Marjan Sharifi Nasab et al. 29
21. Dąbrowski
M,
Szymańska-Garbacz
E,
Miszczyszyn Z, et al. Risk factors for cancer
development in type 2 diabetes: A retrospective
case-control study. BMC cancer. 2016;16(1):785.
[PMID]
[DOI:10.1186/s12885-016-2836-6]
[PMCID]
22. Ramteke P, Deb A, Shepal V, et al. Hyperglycemia
associated metabolic and molecular alterations in
cancer risk, progression, treatment, and mortality.
Cancers. 2019; 11(9):1402.
[PMID]
[DOI:10.3390/cancers11091402]
[PMCID]
23. Ahmadi A, Mobasheri M, Hashemi Nazari SS.
Survival time and relative risk of death in patients
with colorectal cancer in an Iranian population: a
cohort study. J Mazandaran Univ Med Sci.
2014;24(111):2-8.
24. Tahmasbi B, Abedi G, Moosazadeh M, et al.
Determining the survival rate of colorectal cancer
in Iran: A systematic review and meta-analysis.
Asian Pacific journal of cancer prevention: APJCP.
2018; 19(11):3009.
[DOI:10.31557/APJCP.2018.19.11.3009] [PMID]
[PMCID]
25. Akhoond MR, Kazemnejad A, Hajizadeh E, et al.
Comparison of colon and rectum cancer:survival
and prognostic factors. Gastroenterol Hepatol Bed
Bench. 2010;3:177-86.
26. Erickson K, Patterson RE, Flatt SW, et al.
Clinically defined type 2 diabetes mellitus and
prognosis in early-stage breast cancer. J Clin
Oncol. 2011;29(1):54-60.
[DOI:10.1200/JCO.2010.29.3183]
[PMID]
[PMCID]
27. Forouhi NG, Wareham NJ. Epidemiology of
diabetes.
Medicine.
2010;38(11):602-6.
[DOI:10.1016/j.mpmed.2010.08.007]
28. Bardou M, Barkun AN, Martel M. Obesity and
colorectal cancer. Gut. 2013;62(6):933-47.
[DOI:10.1136/gutjnl-2013-304701] [PMID]
29. Murphy TK, Calle EE, Rodriguez C, et al. Body
mass index and colon cancer mortality in a large
prospective study. Am J Epidemiol. 2000;152:84754. [DOI:10.1093/aje/152.9.847] [PMID]
30.
How to Cite This Article:
Sharifi Nasab M, Yazdimoghaddam H, Mohaddes S T, Rakhshani M H. Association between Diabetes and
Controlling Risk Factors with Survival Rate in Colorectal Cancer. J Adv Med Biomed Res. 2022; 30 ( 138) :2429
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Volume 30, January & February 2022
Journal of Advances in Medical and Biomedical Research